Pathologic re-review of NMIBC surgical specimens by genitourinary pathologists led to a change in risk stratification in one-fifth of cases. Pathologic re-review of transurethral resection of bladder ...

Each year, ASCO GU brings together the global genitourinary oncology community for several days of focused learning, debate, ...

The Division of Anatomic Pathology at the University of Alabama at Birmingham, offers a one-year fellowship experience in Genitourinary (GU) pathology. The University of Alabama at Birmingham (UAB) ...

Designing and Validating a Comprehensive Patient-Reported Outcomes Measure for Ambulatory Cancer Settings: The Revised Edmonton Symptom Assessment System for Cancer We retrospectively analyzed ...

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) ...

Geography Should Not Be an “Oncologic Destiny” for Urothelial Cancer: Improving Access to Care by Removing Local, Regional, and International Barriers For more than a decade, advocates have urged ...

The study included a total of 183 patients with genitourinary cancers. Immunity against SARS-CoV-2 appears to wane over time in genitourinary cancer patients following COVID-19 vaccination, suggesting ...

In a recent paper published in the American Journal of Clinical and Experimental Urology, researchers reviewed existing data on the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) ...